Stem Cell Ophthalmology Treatment Study (SCOTS)

This is an interventional treatment trial for Retinal Disease focused on measuring Stem Cells, Bone Marrow Derived Stem Cells, BMSC, BMC (Bone Marrow Cell), Mesenchymal Stem Cells, MSC, Eye Disease, Eye Stem Cells, Ophthalmology, Ophthalmic Disease, Retina, Retinal Disease, Macular Degeneration, Age Related Macular Degeneration, Myopic Macular Degeneration, Geographic Atrophy, Dry Macular Degeneration, Wet Macular Degeneration, Retinal Atrophy, Retinal Dystrophy, Hereditary Retinal Dystrophy, Retinitis Pigmentosa, Stargardt Disease, Cone Dystrophy, Cone Rod Dystrophy, Maculopathy, Optic Nerve Disease, Optic Nerve Atrophy, Optic Atrophy, Ischemic Optic Neuropathy, Optic Nerve Damage, Optic Nerve Compression, Compressive Optic Neuropathy, Devics Syndrome Read More

Inclusion Criteria:

• Have objective, documented damage to the retina or optic nerve unlikely to improve OR
• Have objective, documented damage to the retina or optic nerve that is progressive
• AND have less than or equal to 20/40 best corrected central visual acuity in one or both eyes AND/OR an abnormal visual field in one or both eyes.
• Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.
• If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).
• Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
• Be over the age of 18
• Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.

Exclusion Criteria:

• Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.
• Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.
• Patients who are not capable of providing informed consent.
• Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.